Finasteride for hair loss: a review

References

• Hamilton JB. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci. 1951;53(3):708–728.
   PubMed Web of Science ®Google Scholar
• Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359–1365.
   PubMed Web of Science ®Google Scholar
• Cash TF. The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol. 1992;26(6):926–931.
   PubMed Web of Science ®Google Scholar
• Kaufman KD, Dawber RP. Finasteride, a type 2 5alpha-reductase inhibitor, in the treatment of men with androgenetic alopecia. Expert Opin Investig Drugs. 1999;8(4):403–415.
   PubMedGoogle Scholar
• Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970;45(239):13–23.
   PubMed Web of Science ®Google Scholar
• Nyholt DR, Gillespie NA, Heath AC, et al. Genetic basis of male pattern baldness. J Invest Dermatol. 2003;121(6):1561–1564.
   PubMed Web of Science ®Google Scholar
• PROPECIA® (finasteride) tablets for oral use [Internet]. FDA U.S. Food and Drug Administration; 2016 [cited 2018 Sep 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020788s024lbl.pdf.
   Google Scholar
• Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride male pattern hair loss study group. J Am Acad Dermatol. 1998;39(4):578–589.
   PubMed Web of Science ®Google Scholar
• Leyden J, Dunlap F, Miller B, et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol. 1999;40(6):930–937.
   PubMed Web of Science ®Google Scholar
• Dhurat R, Sharma A, Rudnicka L, et al. 5-Alpha reductase inhibitors in androgenetic alopecia: shifting paradigms, current concepts, comparative efficacy, and safety. Dermatol Ther. 2020;33(3):e13379.
   PubMed Web of Science ®Google Scholar
• Finn DA, Beadles-Bohling AS, Beckley EH, et al. A new look at the 5alpha-reductase inhibitor finasteride . CNS Drug Rev. 2006;12(1):53–76.
   PubMedGoogle Scholar
• Godoy A, Kawinski E, Li Y, et al. 5α-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression. Prostate. 2011;71(10):1033–1046.
   PubMed Web of Science ®Google Scholar
• Nickel JC. Comparison of clinical trials with finasteride and dutasteride. Rev Urol. 2004;6(Suppl 9):S31–S39.
   PubMedGoogle Scholar
• Unger WP, Shapiro R, Unger R, Unger M, editors. Hair transplantation. 5th ed. New York: Informa Healthcare; 2011. p. 538.
   Google Scholar
• Rogers NE, Gupta AK. Medical treatment of male and female pattern hair loss. In: Hair transplantation. 5th ed. Thieme; In press. p. 554.
   Google Scholar
• Liu S, Yamauchi H. Different patterns of 5alpha-reductase expression, cellular distribution, and testosterone metabolism in human follicular dermal papilla cells. Biochem Biophys Res Commun. 2008;368(4):858–864.
   PubMed Web of Science ®Google Scholar
• Huggins C, Stevens RE, Jr, Hodges CV. Studies on prostatic cancer: II. THE effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43(2):209–223.
   Google Scholar
• Hulin-Curtis SL, Petit D, Figg WD, et al. Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer. Future Oncol. 2010;6(12):1897–1913.
   PubMed Web of Science ®Google Scholar
• Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The finasteride study group. N Engl J Med. 1992;327(17):1185–1191.
   PubMed Web of Science ®Google Scholar
• Alwaleedi SA. The involvement of androgens in human hair growth. Am J Biomed Sci. 2015;7(2):105–124.
   Google Scholar
• Andy G, John M, Mirna S, et al. Controversies in the treatment of androgenetic alopecia: the history of finasteride. Dermatol Ther. 2019;32(2):e12647.
   PubMed Web of Science ®Google Scholar
• Rossi A, Anzalone A, Fortuna MC, et al. Multi-therapies in androgenetic alopecia: review and clinical experiences. Dermatol Ther. 2016;29(6):424–432.
   PubMed Web of Science ®Google Scholar
• Price TM, Allen S, Pegram GV. Lack of effect of topical finasteride suggests an endocrine role for dihydrotestosterone. Fertil Steril. 2000;74(2):414–415.
   PubMed Web of Science ®Google Scholar
• Gormley GJ, Stoner E, Rittmaster RS, et al. Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab. 1990;70(4):1136–1141.
   PubMed Web of Science ®Google Scholar
• Dallob AL, Sadick NS, Unger W, et al. The effect of finasteride, a 5alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab. 1994;79(3):703–706.
   PubMed Web of Science ®Google Scholar
• Waldstreicher J, Fiedler V, Hordinsky M, et al. Effects of finasteride on dihydrotestosterone content of scalp skin in men with male pattern baldness. J Invest Dermatol. 1994:615.
   Web of Science ®Google Scholar
• Lee SW, Juhasz M, Mobasher P, et al. A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women. J Drugs Dermatol. 2018;17(4):457–463.
   PubMed Web of Science ®Google Scholar
• Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol. 1992;22(1):1–21.
   PubMed Web of Science ®Google Scholar
• Huskey SW, Dean DC, Miller RR, Rasmusson GH, et al. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metab Dispos. 1995;23(10):1126–1135.
   PubMed Web of Science ®Google Scholar
• Smith RL, Williams RT. Implication of the conjugation of drugs and other exogenous compounds. In: Dutton GJ, editor. Glucuronic acid: free and combined: chemistry, biochmeistry, pharmacology and medicine. New York: Academic Press; 1966. p. 58–69.
   Google Scholar
• Lundahl A, Hedeland M, Bondesson U, et al. The effect of St. John's wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men. Eur J Pharm Sci. 2009;36(4–5):433–443.
   PubMed Web of Science ®Google Scholar
• Carlin JR, Höglund P, Eriksson LO, et al. Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans. Drug Metab Dispos Biol Fate Chem. 1992;20(2):148–155.
   PubMed Web of Science ®Google Scholar
• PROSCAR [Internet]. Merck.com. [revised 2021 Jun; cited 2021 Jun 21]. Available from: https://www.merck.com/research-and-products/proscar/.
   Google Scholar
• Iamsumang W, Leerunyakul K, Suchonwanit P. Finasteride and its potential for the treatment of female pattern hair loss: evidence to date. Drug Des Devel Ther. 2020;14:951–959.
   PubMed Web of Science ®Google Scholar
• Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000;43(5 Pt 1):768–776.
   PubMed Web of Science ®Google Scholar
• Seale LR, Eglini AN, McMichael AJ. Side effects related to 5 α-Reductase inhibitor treatment of hair loss in women: a review. J Drugs Dermatol. 2016;15(4):414–419.
   PubMed Web of Science ®Google Scholar
• Laborde E, Brannigan RE. Effect of 1-mg dose of finasteride on spermatogenesis and pregnancy. J Androl. 2010;31(2):e1–e2.
   PubMedGoogle Scholar
• PROSCAR [package insert]. Whitehouse Station (NJ): Merck Sharp & Dohme Corp.; 2013.
   Google Scholar
• Amory JK, Wang C, Swerdloff RS, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007;92(5):1659–1665.
   PubMed Web of Science ®Google Scholar
• Using Finasteride when trying to conceive [Internet]. Mens Pharmacy Blog; 2018 [cited 2021 Jun 21]. Available from: https://www.menspharmacy.co.uk/blog/finasteride/using-finasteride-when-trying-to-conceive/.
   Google Scholar
• Mazzarella G, Loconsole G, Cammisa G, et al. Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. J Dermatol Treat. 1997;8(3):189–192.
   Web of Science ®Google Scholar
• Caserini M, Radicioni M, Leuratti C, et al. Novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. CP. 2014;52(10):842–849.
   Google Scholar
• Caserini M, Mailland F, Radicioni M, et al. Single and repeated dose of finasteride topical solution in subjects with androgenetic alopecia: a pharmacokinetic and pharmacodynamic study. J Am Acad Dermatol. 2013;68(4 Suppl. 1):AB108.
   Web of Science ®Google Scholar
• Gupta AK, Bamimore MA, Foley KA. Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network Meta-analyses, and an assessment of evidence quality. J Dermatol Treat. 2020:1–11.
   Web of Science ®Google Scholar
• Eun HC, Kwon OS, Yeon JH, Shin HS, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252–258.
   PubMed Web of Science ®Google Scholar
• Gubelin Harcha W, Barboza Martínez J, Tsai T-F, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489–498.e3.
   PubMed Web of Science ®Google Scholar
• Hajheydari Z, Akbari J, Saeedi M, et al. Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2009;75(1):47–51.
   PubMed Web of Science ®Google Scholar
• Van Neste D, Fuh V, Sanchez-Pedreno P, et al. Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol. 2000;143(4):804–810.
   PubMed Web of Science ®Google Scholar
• Roberts JL, Fiedler V, Imperato-McGinley J, et al. Clinical dose ranging studies with finasteride, a type 2 5α-reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol. 1999;41(4):555–563.
   PubMed Web of Science ®Google Scholar
• Shanshanwal SJS, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: a randomized controlled open-label, evaluator-blinded study. Indian J Dermatol Venereol Leprol. 2017;83(1):47–54.
   PubMed Web of Science ®Google Scholar
• RStudio Team. RStudio: integrated development environment for R. Boston (MA): RStudio Team; 2021.
   Google Scholar
• Wang L, Lei Y, Gao Y, et al. Association of finasteride with prostate cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2020;99(15):e19486.
   PubMed Web of Science ®Google Scholar
• Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate. 2004;61(4):332–353.
   PubMed Web of Science ®Google Scholar
• Goodman PJ, Tangen CM, Darke AK, et al. Long-Term effects of finasteride on prostate cancer mortality. N Engl J Med. 2019;380(4):393–394.
   PubMed Web of Science ®Google Scholar
• Traish AM, Zitzmann M. The complex and multifactorial relationship between testosterone deficiency (TD), obesity and vascular disease. Rev Endocr Metab Disord. 2015;16(3):249–268.
   PubMed Web of Science ®Google Scholar
• Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1(1):34–45.
   PubMed Web of Science ®Google Scholar
• Said MA, Mehta A. The impact of 5α-reductase inhibitor use for male pattern hair loss on men's health. Curr Urol Rep. 2018;19(8):65.
   PubMed Web of Science ®Google Scholar
• Arca E, Açıkgöz G, Taştan HB, et al. An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia. Dermatol Basel Switz. 2004;209(2):117–125.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014–1023.
   PubMed Web of Science ®Google Scholar
• Khandpur S, Suman M, Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol. 2002;29(8):489–498.
   PubMed Web of Science ®Google Scholar
• Theisen KM, Park SY, Jeong K, et al. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol. 2019;124(4):223–300.
   Google Scholar
• Price VH, Menefee E, Sanchez M, et al. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results. J Am Acad Dermatol. 2006;55(1):71–74.
   PubMed Web of Science ®Google Scholar
• Rossi A, Cantisani C, Scarno M, et al. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up. Dermatol Ther. 2011;24(4):455–461.
   PubMed Web of Science ®Google Scholar
• Sato A, Takeda A. Evaluation of efficacy and safety of finasteride 1 mg in 3177 japanese men with androgenetic alopecia. J Dermatol. 2012;39(1):27–32.
   PubMed Web of Science ®Google Scholar
• Yanagisawa M, Fujimaki H, Takeda A, et al. Long-term (10-year) efficacy of finasteride in 523 japanese men with androgenetic alopecia. Clin Res Trials. 2019;5. DOI:10.15761/CRT.1000273. Available from: https://www.oatext.com/Long-term-(10-year)-efficacy-of-finasteride-in-523-Japanese-men-with-androgenetic-alopecia.php
   Google Scholar
• Yeon JH, Jung JY, Choi JW, et al. 5 mg/day finasteride treatment for normoandrogenic asian women with female pattern hair loss. J Eur Acad Dermatol Venereol JEADV. 2011;25(2):211–214.
   PubMed Web of Science ®Google Scholar
• Oliveira-Soares R, E Silva J, Correia M, et al. Finasteride 5 mg/day treatment of patterned hair loss in normo-androgenetic postmenopausal women. Int J Trichology. 2013;5(1):22–25.
   PubMedGoogle Scholar
• Oliveira-Soares R, André MC, Peres-Correia M. Adverse effects with finasteride 5 mg/day for patterned hair loss in premenopausal women. Int J Trichology. 2018;10(1):48–50.
   PubMedGoogle Scholar
• Belknap SM, Aslam I, Kiguradze T, et al. Adverse event reporting in clinical trials of finasteride for androgenic Alopecia: a meta-analysis. JAMA Dermatol. 2015;151(6):600–606.
   PubMed Web of Science ®Google Scholar
• Stough DB, Rao NA, Kaufman KD, et al. Finasteride improves male pattern hair loss in a randomized study in identical twins. Eur J Dermatol. 2002;12(1):32–37.
   PubMed Web of Science ®Google Scholar
• Rossi A, Mari E, Scarno M, et al. Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. Int J Immunopathol Pharmacol. 2012;25(4):1167–1173.
   PubMed Web of Science ®Google Scholar
• Lin J-H, Chen W-C. Finasteride in the treatment of taiwanese men with androgenetic alopecia: a 12-month open-label study. Kaohsiung J Med Sci. 2002;18(8):379–385.
   PubMedGoogle Scholar
• Haber RS, Gupta AK, Epstein E, et al. Finasteride for androgenetic alopecia is not associated with sexual dysfunction: a survey-based, single-centre, controlled study. J Eur Acad Dermatol Venereol. 2019;33(7):1393–1397.
   PubMed Web of Science ®Google Scholar
• Mysore V. Finasteride and sexual side effects. Indian Dermatol Online J. 2012;3(1):62–65.
   PubMedGoogle Scholar
• Hirshburg JM, Kelsey PA, Therrien CA, et al. Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): a systematic review. J Clin Aesthetic Dermatol. 2016;9(7):56–62.
   PubMedGoogle Scholar
• Irwig MS. Finasteride and suicide: a postmarketing case series. Dermatology. 2020;236(6):540–545.
   PubMed Web of Science ®Google Scholar
• Irwig MS. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry. 2012;73(09):1220–1223.
   PubMedGoogle Scholar
• Research C for DE and October – December 2009 | Potential signals of serious risks/new safety information identified by the adverse event reporting system (AERS). FDA [Internet]; 2021 Feb 3 [cited 2021 Jun 21]. Available from: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/october-december-2009-potential-signals-serious-risksnew-safety-information-identified-adverse-event.
   Google Scholar
• Ali AK, Heran BS, Etminan M. Persistent sexual dysfunction and suicidal ideation in young men treated with low-dose finasteride: a pharmacovigilance study. Pharmacotherapy. 2015;35(7):687–695.
   PubMed Web of Science ®Google Scholar
• Gupta MA, Vujcic B, Sheridan AD, et al. Finasteride is associated with a higher odds of obstructive sleep apnea (OSA): results from the us FDA adverse events reporting system (FAERS). Sleep. 2018;41(suppl_1):A340–A341.
   Google Scholar
• Gupta AK, Carviel J, MacLeod MA, et al. Assessing finasteride-associated sexual dysfunction using the FAERS database. J Eur Acad Dermatol Venereol. 2017;31(6):1069–1075.
   PubMed Web of Science ®Google Scholar
• Baas WR, Butcher MJ, Lwin A, et al. A review of the FAERS data on 5-Alpha reductase inhibitors: implications for postfinasteride syndrome. Urology. 2018;120:143–149.
   PubMed Web of Science ®Google Scholar
• Traish AM. Post-finasteride syndrome: a surmountable challenge for clinicians. Fertil Steril. 2020;113(1):21–50.
   PubMed Web of Science ®Google Scholar
• BreckenridgeA, Woods K. Great Britain, medicines and healthcare products regulatory agency. In Breckenridge A, Woods K, editors. Medicines and healthcare products regulatory agency annual report and accounts 2010/11. London: The Stationery Office; 2011.
   Google Scholar
• Traish AM, Mulgaonkar A, Giordano N. The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. Korean J Urol. 2014;55(6):367–379.
   PubMedGoogle Scholar
• Frye CA, Walf AA. Changes in progesterone metabolites in the hippocampus can modulate open field and forced swim test behavior of proestrous rats. Horm Behav. 2002;41(3):306–315.
   PubMed Web of Science ®Google Scholar
• Frye CA, Edinger KL. Testosterone's metabolism in the hippocampus may mediate its anti-anxiety effects in male rats . Pharmacol Biochem Behav. 2004;78(3):473–481.
   PubMed Web of Science ®Google Scholar
• Trüeb RM, Régnier A, Dutra Rezende H, et al. Post-Finasteride syndrome: an induced delusional disorder with the potential of a mass psychogenic illness? Skin Appendage Disord. 2019;5(5):320–326.
   PubMed Web of Science ®Google Scholar
• Tacklind J, Fink HA, Macdonald R, et al. Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2010;(10):CD006015.
   PubMed Web of Science ®Google Scholar